Need Help?

Whole exome and transcriptome sequencing of biliary tract cancer

To uncover the full repertoire of genetic and transcriptomic landscape of biliary tract cancer (BTC), we molecularly characterized BTC based on genetic and transcriptomic alteration profiles.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001001076 Illumina HiSeq 2000 239
EGAD00001001693 Illumina HiSeq 2000 182
Publications Citations
Therapeutic Rationale to Target Highly Expressed Aurora kinase A Conferring Poor Prognosis in Cholangiocarcinoma.
J Cancer 11: 2020 2241-2251
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
J Hepatol 73: 2020 315-327
Hotspots of Aberrant Enhancer Activity in Fibrolamellar Carcinoma Reveal Candidate Oncogenic Pathways and Therapeutic Vulnerabilities.
Cell Rep 31: 2020 107509
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
J Exp Clin Cancer Res 41: 2022 183
Comprehensive transcriptomic analysis to identify biological and clinical differences in cholangiocarcinoma.
Cancer Med 12: 2023 10156-10168
Preoperative immunological plasma markers TRAIL, CSF1 and TIE2 predict survival after resection for biliary tract cancer.
Front Oncol 13: 2023 1169537
Molecular profiling reveals potential targets in cholangiocarcinoma.
World J Gastroenterol 29: 2023 4053-4071